KemPharm $KMPH signed a license agreement with Acura Pharmaceuticals $ACUR for its Aversion Technology which deters drug prescription drug abuse by turning into a gel when dissolved and contains compounds that irritate the nasal passages if the drug is snorted. As per the terms of the treatment, Acura will receive an upfront fee of $3.5 million and will earn low-single digit royalties on net sales. KemPharm will retain development and commercialization rights for up to three immediate-release product candidates and will have an option to use Aversion Technology in more than three products. Acura will be eligible for additional payments should KemPharm exercise the option.